Business
Mirum Pharmaceuticals to Participate in September Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in five investor conferences
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in five investor conferences taking place virtually throughout the month of September.\n\nCiti 16th Annual BioPharma Virtual Conference\nSeptember 10, 2021\nFormat: One-on-one meetings\n\nH.C. Wainwright 23rd Annual Global Investor Conference\nSeptember 13-14, 2021\nFormat: Company presentation (available September 13 at 7:00 a.m. ET) and one-one-meetings.\n\nBaird Global Healthcare Conference\nSeptember 14-15, 2021\nFormat: Company presentation (September 14 at 12:50 p.m. ET) and one-on-one meetings.\n\nLeerink CyberRX Series 1x1 Event\nSeptember 22-23, 2021\nFormat: One-on-one meetings.\n\nCantor Global Healthcare Conference\nSeptember 27-29, 2021\nFormat: Company presentation (September 27 at 2:40 p.m. ET) and one-on-one meetings.\n\nVisit the Investors and Media section of Mirum’s corporate website for additional information.\n\nAbout Mirum Pharmaceuticals, Inc.\n\nMirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS. The NDA has been accepted for priority review by the FDA with a PDUFA action date of September 29, 2021. Additionally, Mirum’s marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency. Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis. For more information, visit MirumPharma.com.\n\nTo augment its pipeline in cholestatic liver disease, Mirum has acquired the exclusive option to develop and commercialize gene therapy programs VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively, from Vivet Therapeutics SAS, following preclinical evaluation and investigational new drug-enabling studies.\n\nFollow Mirum on Twitter, Facebook, Lin...